Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Aptose Biosciences ( (TSE:APS) ) has issued an announcement.
On February 13, 2025, Aptose Biosciences announced the establishment of a $25 million Committed Equity Facility and a new at-the-market (ATM) facility with an institutional investor. This agreement allows Aptose to sell up to $25 million in common shares over 24 months, subject to regulatory conditions. The company also entered a sales agreement for ATM distributions on Nasdaq, with a total offering price of up to $1 million. These moves aim to strengthen Aptose’s financial position and support its ongoing development of treatments for AML.
More about Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company focusing on precision medicines for oncology, particularly in hematology. The company is developing tuspetinib (TUS), an oral kinase inhibitor, for the treatment of acute myeloid leukemia (AML), both as a monotherapy and in combination therapies.
YTD Price Performance: -5.00%
Average Trading Volume: 9,169,134
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $12.85M
See more insights into APS stock on TipRanks’ Stock Analysis page.
